<DOC>
	<DOCNO>NCT00081653</DOCNO>
	<brief_summary>This 2 arm study ass long-term efficacy safety oral treatment 100mg 150mg Bonviva woman post-menopausal osteoporosis previously complete Bonviva study BM16549 ( MOBILE study ) . Patients receive Bonviva either 100mg po monthly , 150mg po monthly . Patients also receive daily supplementation vitamin D calcium . The anticipated time study treatment 2+ year , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Bonviva ( Ibandronate ) Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>successful completion Bonviva study BM16549 , least 75 % compliance ; ambulatory . malignant disease diagnose within previous 12 year ( except basal cell cancer successfully remove ) ; breast cancer diagnose within previous 22 year .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>